In our 2024 article on India’s IVF sector (https://medium.com/@loestroadvisors/indias-ivf-boom-hope-science-and-business-18beb67e8ceb) , we described a market at an inflection point- high structural demand, fragmented supply, improving awareness, and growing investor appetite. The broad thesis was compelling: a sector with the economics of specialty healthcare, the scalability of a service chain, and a decade of demographic tailwind ahead of it. Twelve months later, all of those structural factors remain in place. But the sector has also produced its first major fraud scandal, the largest domestic chain has reported essentially flat cycle volumes, India’s first listed fertility company has given public markets a pricing reference, and the range of M&A activity has widened considerably.

1. Domestic Platform Plays Are Getting More Sophisticated

The two most active domestic acquirers of the past year — Indira IVF and Nova IVF — have used acquisitions not just to add headcount but to fill specific geographic and strategic gaps.

Consolidation by Larger Players in 2025–26Nova IVF acquires CRAFT Hospitals, Kerala (March 2026, ~$40 million): Nova IVF acquired a majority stake in CRAFT Hospitals, a well-established Kerala-based chain. CRAFT gives Nova an anchor presence and a credible brand to build upon, with plans to expand to up to 10 additional centres in the state. The deal model — buying established regional brand, layering in centralised lab protocols and referral infrastructure — has become the standard playbook for organised chains entering new geographies.Indira IVF acquires stake in Banker IVF, Gujarat (June 2025): EQT-backed Indira IVF acquired a stake in Ahmedabad-based Banker IVF, one of Gujarat’s most recognised fertility clinics with nearly three decades of patient history. The rationale is straightforward — Banker’s brand equity and established patient base provides Indira a faster and more credible entry into the Gujarat market than a greenfield centre could deliver. This type of legacy-clinic acquisition is increasingly the preferred expansion route for organised chains in markets where brand trust takes years to build.Indira IVF acquires Pondicherry fertility hospital (September 2025): Indira followed the Gujarat acquisition with the purchase of a Pondicherry-based fertility hospital, described as part of a southward expansion strategy with a digital integration component — centralising clinical data and protocols across a geographically dispersed network.

2. Global Capital Is Now Actively Entering Indian Fertility Assets

IVI RMA Global acquires ART Fertility Clinics (~$400–450 million, July 2025 / January 2026): KKR-backed IVI RMA Global, one of the world’s largest fertility groups, moved to acquire ART Fertility Clinics. ART operates 14 centres — 11 in India and 3 in the UAE. IVI RMA formally completed the Middle East component in January 2026, adding it as its fifth global operating region. The deal also signals something strategically important: European fertility platforms are not merely watching India from a distance. They are using Indian clinical infrastructure as a base to serve demand from the Middle East, South Asia, and global medical tourism flows.

3. Not Every Adjacency Play Has Worked — The Redcliffe Divestiture

Redcliffe Labs sells Crysta IVF to Moon Care (April 2026, ~₹100 crore): Diagnostic chain Redcliffe Labs divested its fertility arm Crysta IVF to Moon Care Pvt Ltd (MMG Group) for approximately ₹100 crore. The stated reason — sharpening focus on core diagnostics — is a polished way of acknowledging that owning and operating an IVF chain is a meaningfully different business from running a diagnostics network. The Redcliffe exit is a useful data point for any diagnostics or hospital group contemplating a lateral move into fertility: the synergies may look clear on a slide deck but are harder to capture operationally.

4. New Business Models Are Entering the Market and Challenging the Traditional Clinic Playbook

Alongside the established chain-versus-standalone dynamic, a new category of player has emerged in Indian fertility over the past twelve months: technology-enabled, asset-light aggregators that partner with independent clinics rather than owning them. At the same time, established players are broadening what they offer — moving from IVF into the wider women’s health continuum.

A. Asset-Light Aggregators Are Attracting Serious Venture Capital

The premise of the asset-light fertility model is that the biggest constraint in Indian IVF is not capital for new clinics — it is clinical standardisation, patient trust, and referral access. Aggregators address this by partnering with independent clinics, supplying standardised protocols and technology, and building a brand layer above the fragmented clinic supply. The model requires less capital to scale than chain ownership and can potentially grow faster.

● Pluro Fertility — ₹125 crore Series A (October 2025): Pluro raised ₹125 crore in a Series A led by Bessemer Venture Partners at a post-money valuation of approximately ₹1,000 crore. This values the business at roughly 7–8x implied annual revenue — a multiple that reflects investor confidence in the model’s potential scale, not its current size. Pluro’s approach is to build a network of partner clinics that operate under its quality protocols and brand, without Pluro directly owning the real estate or lab equipment.

● Luma Fertility — $4 million seed (Peak XV’s Surge, mid-2025): Luma raised a $4 million seed round from Peak XV’s Surge, positioning itself as a tech-forward fertility platform targeting digitally-engaged, younger urban patients.

● India IVF Clinic — $1.25 million seed (Tomorrow Capital, late 2024): India IVF Clinic raised a smaller seed round, building a similar aggregation model targeting the mid-market and Tier-2 geographies.

The unresolved question for all three platforms — and the question every growth-stage investor will focus on — is clinical: does standardised protocol delivery across independently owned facilities actually produce the same success rates as a company-owned chain? The answer will be visible in outcome data over the next 18–24 months. Until then, valuations are largely a bet on the model.

B. Established Chains Are Expanding Beyond IVF Into Women’s Health

Indira IVF launched MatCare Maternity & Child Hospital, Varanasi, Pune & Prayagraj (March 2025): Indira IVF officially entered the maternity and child healthcare segment with the launch of MatCare — a full-service facility offering advanced delivery rooms, Level III NICU, fetal medicine, high-risk pregnancy management, neonatal surgery, and postnatal rehabilitation. This is not simply an adjacent service — it is a strategic positioning move. By owning the patient relationship from fertility treatment through delivery and newborn care, Indira is building a continuum-of-care model that increases revenue per patient, reduces patient attrition, and makes the platform narrative far more compelling to investors.

India Now Has Its First Listed IVF Company — and It Has Changed the Valuation Conversation

While attention was focused on when Indira IVF would file its much-anticipated IPO, a smaller but significant event occurred: Gaudium IVF and Women Health became India’s first listed pure-play fertility company, completing an IPO and listing on BSE and NSE on February 27, 2026.

What Happened

IPO size: ₹165 crore (₹90 crore fresh issue + ₹75 crore offer for sale)Price band: ₹75–79 per shareSubscription: 7.27x overall — retail at 7.6x, NII category at 14x, QIB at 1.62xListing: February 27, 2026 on BSE and NSE

Financial Profile at the Time of Listing

FY25 revenue: ₹70.96 crore (up 47% from ₹48.15 crore in FY24)FY25 EBITDA: ₹29 crore (up from ₹19 crore in FY24) ~ 41% EBITDA MarginFY25 PAT: ₹19.13 crore (up from ₹10.32 crore in FY24)Network: 36 centres at the time of listingEV/EBITDA at listing: approximately 18–20x FY25 earningsP/E at listing: approximately 23–30x FY25 earnings

Why This Matters Beyond the Gaudium Story

Two things stand out. First, a public market reference point now exists for IVF valuations in India. Even at Gaudium’s modest scale — ₹71 crore in revenue, 36 centres — the market assigned a multiple of 23–30x earnings and an 8x revenue multiple. This establishes a floor for how every other fertility business in India can be priced in future fundraising, M&A, or IPO discussions. Second, the IPO’s strong retail and NII subscription confirmed genuine investor appetite for fertility-sector exposure at a broad market level, not just among specialist PE funds. That demand depth will influence how Indira IVF structures and prices its own listing.

India’s Largest IVF Chain Has Hit a Volume Ceiling — and the Industry Must Take Notice

The most important data point from the past twelve months did not come from a deal announcement or an IPO. It came from a routine credit rating update. ICRA’s September 2025 rating report on Indira IVF contained a number that should prompt a serious re-examination of assumptions across the sector.

Source: ICRA Rating Report, September 2025

What This Means

Indira IVF is India’s largest fertility chain — 165+ centres, 20+ states, 340+ specialists, and the deepest brand recognition in the sector. If any organised player had the scale to capture market volume growth, it is Indira. The fact that its cycle count has not grown in a full financial year raises a fundamental question about the sector’s growth dynamics.

The dominant market thesis has held that India performs approximately 300,000 IVF cycles per year, and this number should compound at 12–15% annually over the next decade. There are two possible explanations for why the sector’s largest player is showing zero volume growth, and both are worth engaging with seriously:

The overall market is growing more slowly than projected. Rising awareness has not yet translated into the volume of treatment-seeking behaviour that optimistic projections assumed. Cost barriers, social stigma, and access gaps still limit conversion from awareness to treatment.The market is growing, but growth is being captured by others. Smaller regional clinics, new Tier-2 city entrants, and the emerging VC-backed aggregators may be absorbing the incremental demand that would previously have flowed to organised chains. If true, this is equally concerning for the platform thesis — it suggests that Indira’s scale and brand recognition are not translating into volume capture in a competitive market.

The answer is probably a combination of both. For investors underwriting IVF businesses on the assumption of 15–20% cycle volume growth per annum, the Indira data is a direct input that warrants re-examination. The right metric to ask for is not how many centres a chain operates — it is what same-centre cycle growth looks like in year three and year five of operations.

Revenue growing while volume stagnates is a short-term story. A company can improve realisations per cycle for a few years through pricing power and ancillary revenue. But a fertility business that is not growing its clinical volume is, ultimately, not growing its business. Investors should track cycle counts as closely as they track revenue.

Regulation Is Tightening — Reinforcing the Case for Organised Players

IVF is one of the most heavily regulated segments in Indian healthcare, requiring a multi-layered compliance framework to operate.

Regulatory Landscape (Snapshot)

ART (Regulation) Act, 2021: Mandatory registration; strict controls on gamete usage; criminal liability for violationsSurrogacy (Regulation) Act, 2021: Ban on commercial surrogacy; tightly governed altruistic frameworkICMR Guidelines: Clinical standards and reporting normsState-level Clinical Establishment registrationsOther requirements: PNDT compliance, drug licences, biomedical waste management

A typical IVF clinic requires 8–10 licenses to be fully compliant.

Structural Implication

Compliance intensity creates a clear moat for organised chains with institutional processes and governance~90% of India’s ~6,500 IVF clinics remain independent and under-institutionalised, making compliance a structural challengeThis regulatory asymmetry is a key driver of sector consolidation

Sector Risk Highlight (2025 Case)

A high-profile fraud case in 2025 exposed gaps in enforcement and governance within parts of the unorganised segment, triggering regulatory scrutiny and reputational overhang for the sector.

What we think: The LoEstro view

We are watching three dynamics play out simultaneously in Indian IVF, and each leads to a different set of implications for operators and investors.

First, the valuation floor has moved up. Between the BPEA-EQT/Indira IVF deal at ~$1.1 billion (2023), the ART Fertility exit at $400–450 million (2025), and the Pluro Series A at ₹1,000 crore pre-revenue (2025), the market is clearly pricing IVF platforms at a premium to traditional hospital chains. EV/EBITDA multiples for mature platforms appear to be in the 16–20x range, with early-stage ventures commanding even higher multiples on a revenue basis. For promoters considering a capital event, this is a favourable window.

Second, the volume growth thesis needs recalibration. The market-size projections ($1 billion in 2024, growing at 13–16% CAGR) have been cited in every IVF pitch deck for two years. But the largest player’s volume stagnation suggests that converting India’s theoretical IVF demand (210 cycles per million population vs. ~2,000 in Europe) into actual cycle volumes is harder than the top-line numbers imply. Affordability, awareness in Tier 2/3 cities, cultural barriers, and regulatory friction are all real impediments. Revenue growth in the near term is more likely to come from pricing power and service mix than from volume expansion.

Third, consolidation has further to run, but the model is evolving. The next wave of deals won’t just be PE funds buying chains outright. Pluro’s aggregation model, Indira’s adjacency into mother-and-childcare, and the entry of global players like IVI RMA suggest that the M&A landscape is becoming more creative. We expect to see more partnership-driven consolidation (similar to Pluro), more vertical integration (IVF + maternity + diagnostics), and possibly cross-border transactions as global fertility platforms view India as a growth market.

LoEstro Advisors is a healthcare & education focused investment bank. Over the last four years, we have advised on $1.2 billion+ in closed transactions across healthcare, education, consumer, and technology.

If you are a fertility clinic/healthcare founder or promoter thinking about your next chapter — whether that is bringing in institutional capital, evaluating a strategic partnership, or understanding what your business is worth in the current market — we would like to have that conversation.

Get in touch: rakesh.gupta@loestro.com, Soumya@loestro.com